jurnalul român de psihofarmacologie romanian journal of ...
jurnalul român de psihofarmacologie romanian journal of ... jurnalul român de psihofarmacologie romanian journal of ...
180. Mueller-Siecheneder F, Mueller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998; 18:111-120. 181. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. J Clin Psychiatry 1998; 59:69-75. 182. Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999; 99:160-170. 183. Schillevoort I, de Boer A, Herings RM, Roos RA, Jansen PA, Leufkens HG. Antipsychotic- induced extrapyramidal syndromes. Risperidone compared with low-end high-potency conventional antipsychotic drugs. Eur J Clin Pharmacol 2001; 57:327-331. 184. Marckianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride or haloperidol. Eur Arch Psychiatry Clin Neurosci 2001; 251:141-146. 185. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM. Weight gain in adolescent treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998; 8:151-159. 186. Conley RR. Risperidone side effects. J Clin Psychiatry 2000; 8:20-23. 187. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wosniak PJ, Sebree TB, Wallin BA, Kashkin KB. The Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154:782-791. 188. Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 1997; 12(Suppl. 1):29-35. 189. Martin PT, Grebb JA, Schmitz P, Sebree T, Kashkin K and the M92-762 and M92-817 Sertindole Research Groups. Efficacy and safety of sertindole in two double-blind, placebo- comtrolled trials of schizophrenic patients. Schizophr Res 1994; 11:107. 190. Van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB, Sertindole Study Group. A randomized controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124:168-175. 191. Dunn JC, Fitton A. Sertindole. CNS Drugs 1996; 5:224-230. 147
192. Hale AS. A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol 1998; 13(Suppl. 3):65-70. 193. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka NJ, Saunders JC, Krueger J, Bradley P, San L, Bernardo M, Reinstein M, Breier A. A double-blind, placebo controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158:1149-1151. 194. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch M, Rizk R, Walker D, Tran P, Beier A. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21:389-397. 195. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR. Ziprasidone Study Group. Ziprasidone 40 and 20 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo controlled trial. Psychopharmacology 1998; 140:173-184. 196. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18:296-304. 197. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone IM Study Group. J Clin Psychiatry 2000; 61:933-941. 198. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology 2001; 155:128-134. 199. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62:12-18. 200. Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 39:292-299. 201. Gunn KP, Harrigan EP, Heym J. The safety and tolerability of ziprasidone treatment. In: Critical Issues in the treatment of schizophrenia. Brunello N, Racagni G, Langer SZ, Mendlewicz J (eds.) Kerger, Basel 1995; 10:172-177. 202. Miceli JJ. Cardiovascular safety profile of ziprasidone (Abstract). World J Biol Psychiatry 2001; 2:384. 148
- Page 101 and 102: decât pentru loratadină, fără d
- Page 103 and 104: viteză de 95 km/h, reprezintă o c
- Page 105 and 106: 6. Hindmarch, I., Shamsi, Z., 1999
- Page 107 and 108: 35. Tashiro, M., Mochizuki, H., Iwa
- Page 109 and 110: În insuficienţa hepatică cronic
- Page 111 and 112: În hiperamoniemia moderată cronic
- Page 113 and 114: c. GABA (acid gamma aminobutiric) e
- Page 115 and 116: Iată deci cum factori diferiţi, c
- Page 117 and 118: Perspectiva psihosocială Buss - 19
- Page 119 and 120: În sindromul Kluver-Bucy (ablaţia
- Page 121 and 122: Bibliografie selectivă 1. Allen, T
- Page 123 and 124: International Journal for Postgradu
- Page 125 and 126: familia pacientului, formularea pla
- Page 127 and 128: Participarea familiei trebuie să i
- Page 129 and 130: VI. Antipsihoticele convenţionale:
- Page 131 and 132: Chiar dacă toate aceste medicament
- Page 133 and 134: ezistenţi la tratament (19, 35, 36
- Page 135 and 136: În studiile controlate în alte tu
- Page 137 and 138: Ib. Iloperidona Iloperidona este un
- Page 139 and 140: 9. American Psychiatric Association
- Page 141 and 142: 42. Casey DE. Side effects profiles
- Page 143 and 144: 67. von Fischer-Cornelssen K, Ferne
- Page 145 and 146: 93. Klieser E, Lehmann E, Kinzler E
- Page 147 and 148: 121. Beasley Jr CM, Hamilton SH, Cr
- Page 149 and 150: schizophrenia presenting psychotic
- Page 151: 168. Segal J, Berk M, Brook S. Risp
- Page 155 and 156: 215. Hori M, Suzuki M, Shiraishu H,
- Page 157 and 158: 240. Honigfeld G, Patin J. A two-ye
- Page 159 and 160: 266. Barnas C, Stuppaeck CH, Miller
- Page 161 and 162: I. Strategii de comunicare 1. COMUN
- Page 163 and 164: 2.2 Recomandări Profesioniştii as
- Page 165 and 166: 4.2 Recomandări � Cel puţin în
- Page 167 and 168: � Trebuie elaborate şi larg dist
- Page 169 and 170: schizofrenie nu au „personalită
- Page 171 and 172: instituţionalizări (18). Cu toate
- Page 173 and 174: 9. Revicki DA. Pharmacoeconomic eva
- Page 175: Instructions to authors The text mu
180. Mueller-Siechene<strong>de</strong>r F, Mueller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O.<br />
Risperidone versus haloperidol and amitriptyline in the treatment <strong>of</strong> patients with a<br />
combined psychotic and <strong>de</strong>pressive syndrome. J Clin Psychopharmacol 1998; 18:111-120.<br />
181. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The<br />
prevalence <strong>of</strong> acute extrapyramidal signs and symptoms in patients treated with clozapine,<br />
risperidone and conventional antipsychotics. J Clin Psychiatry 1998; 59:69-75.<br />
182. Lemmens P, Brecher M, Van Baelen B. A combined analysis <strong>of</strong> double-blind studies with<br />
risperidone vs placebo and other antipsychotic agents: factors associated with<br />
extrapyramidal symptoms. Acta Psychiatr Scand 1999; 99:160-170.<br />
183. Schillevoort I, <strong>de</strong> Boer A, Herings RM, Roos RA, Jansen PA, Leufkens HG. Antipsychotic-<br />
induced extrapyramidal syndromes. Risperidone compared with low-end high-potency<br />
conventional antipsychotic drugs. Eur J Clin Pharmacol 2001; 57:327-331.<br />
184. Marckianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivities <strong>of</strong> the pituitary<br />
dopamine system in male schizophrenic patients during treatment with clozapine,<br />
olanzapine, risperidone, sulpiri<strong>de</strong> or haloperidol. Eur Arch Psychiatry Clin Neurosci 2001;<br />
251:141-146.<br />
185. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM. Weight gain in adolescent treated<br />
with risperidone and conventional antipsychotics over six months. J Child Adolesc<br />
Psychopharmacol 1998; 8:151-159.<br />
186. Conley RR. Risperidone si<strong>de</strong> effects. J Clin Psychiatry 2000; 8:20-23.<br />
187. Zimbr<strong>of</strong>f DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wosniak PJ, Sebree TB,<br />
Wallin BA, Kashkin KB. The Sertindole Study Group. Controlled, dose-response study <strong>of</strong><br />
sertindole and haloperidol in the treatment <strong>of</strong> schizophrenia. Am J Psychiatry 1997;<br />
154:782-791.<br />
188. Tamminga CA, Mack RJ, Granneman GR, Silber CJ, Kashkin KB. Sertindole in the<br />
treatment <strong>of</strong> psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol<br />
1997; 12(Suppl. 1):29-35.<br />
189. Martin PT, Grebb JA, Schmitz P, Sebree T, Kashkin K and the M92-762 and M92-817<br />
Sertindole Research Groups. Efficacy and safety <strong>of</strong> sertindole in two double-blind, placebo-<br />
comtrolled trials <strong>of</strong> schizophrenic patients. Schizophr Res 1994; 11:107.<br />
190. Van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB, Sertindole Study<br />
Group. A randomized controlled, dose-ranging trial <strong>of</strong> sertindole in patients with<br />
schizophrenia. Psychopharmacology 1996; 124:168-175.<br />
191. Dunn JC, Fitton A. Sertindole. CNS Drugs 1996; 5:224-230.<br />
147
Change language